Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 352 participants.

Also called NCT07084259

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 352 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07084259
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07084259. Randomized; no masking; primary purpose treatment. Start 2025-07 (anticipated); primary completion 2030-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Single Dose PCSK9 Inhibitor to Improve Cardiovascular Outcomes After PCI: A Pilot Study
Acronym
HANYANG-PICK
Intervention (Drug)
PCSK9 inhibitor
Intervention (Drug)
Standard Lipid-Lowering Therapy
Lead sponsor
Hanyang University Seoul Hospital (class: other)
Collaborator
DOTTER Inc. (class: not stated)

Record details

Record id
cardio:ct-nct07084259
Content hash
7dac41e22c19b72d23f317e88c11c90e22d8841abed8bb3cc8951ca2c345d515